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Abstract
Purpose To determine whether the presence of vitreomacular interface abnormalities (VMIA) in patients with diabetic macular
oedema (DMO) modifies the response to ranibizumab.
Methods Medical records and spectral-domain optical coherence tomography (SD-OCT) scans of consecutive patients with
centre-involving DMO initiating therapy with ranibizumab between December 2013 and March 2014 at the Belfast Health and
Social Care Trust were reviewed. Patients were identified through an electronic database. Demographics; systemic baseline
characteristics; history of previous ocular surgery/laser; best-corrected visual acuity (BCVA), central retinal thickness (CRT) and
stage of retinopathy at presentation; and BCVA, CRT and presence/absence of fluid at the last follow-up were recorded. OCT
scans were reviewed by amasked investigator who graded them for the presence/absence of VMIA at baseline and during follow-
up and for the change in the posterior hyaloid face during follow-up. The association between (1) VMIA at baseline and (2) the
change in the posterior hyaloid face during the follow-up and functional/anatomical outcomes was evaluated.
Results One hundred forty-six eyes of 100 patients (mean age 63.5 years) followed for a mean of 9 months (range 2–14 months;
only 9/146 dropped to follow-up before month 6) were included. Statistically significant differences were observed at baseline in
BCVA (p = 0.007), previous macular laser and panretinal photocoagulation (PRP) (p = 0.006) and previous cataract surgery (p =
0.01) between eyes with and without VMIA, with better levels of vision, higher frequency of macular laser and lower frequency
of PRP in eyes where no VMIA was present. Multivariable regression analysis did not disclose any statistically significant
associations between VMIA at baseline or change in the posterior hyaloid face during the follow-up and functional and ana-
tomical outcomes following treatment.
Conclusion VMIA are associated with worse presenting vision in patients with DMO; VMIA or change in the posterior hyaloid
face during the follow-up did not modify the response to ranibizumab in this study.
Keywords Retina . Diabetic macular oedema . OCT imaging . Vitreomacular interface abnormalities . Intravitreal anti-VEGF
injection
Introduction
The vitreomacular interface (VMI) gained greater scientific
interest since the advent of optical coherence tomography
(OCT). Spectral-domain OCT (SD-OCT) allows excellent vi-
sualisation of the VMI, enabling the study of the role of VMI
abnormalities (VMIA) in the development of macular disease
and the response to treatment. Vitreomacular traction (VMT),
a form of VMIA [1], has been proposed as one of many
aetiological factors for the development of diabetic macular
oedema (DMO) [2]. Relief of traction, either spontaneously or
through vitrectomy, may promote DMO resolution in some
cases [3–5].
The reported prevalence of VMIA in patients with DMO
ranges from 6.6 to 52.1%, depending on the diagnostic criteria
and retinal imaging modality used [2, 6–10]. Only a few of
these studies, however, used SD-OCT [9, 10]. Recently,
Akbar Khan et al. used SD-OCT to image a cohort of patients
Presented at the 39th Annual Meeting of the USA Macula Society,
February 24–27, 2016, Miami, Florida, USA
* Noemi Lois
n.lois@qub.ac.uk
1 Department of Ophthalmology, Belfast Health and Social Care Trust,
Belfast, UK
2 Wellcome-Wolfson Institute for Experimental Medicine, Queen’s
University, Belfast, UK
Graefe's Archive for Clinical and Experimental Ophthalmology
https://doi.org/10.1007/s00417-018-4009-6
with centre-involving DMO undergoing macular laser treat-
ment and found a VMIA prevalence of 26% in this group [9].
Anti-vascular endothelial growth factor (anti-VEGF)
agents have revolutionised the management of DMO.
Clinical studies exploring the effect of the presence or absence
of VMIA on the response to anti-VEGF treatment in DMO
patients are scarce [10, 11]. Elucidating the effect of VMIA on
the response to anti-VEGFs is important to guide the manage-
ment of patients with DMO; if VMIAwere associated with a
worse response to treatment, early vitrectomy could be
considered.
Intravitreal injections of anti-VEGFs (or other substances)
may alter the anatomical structure of the vitreous leading to
changes in the status of the posterior hyaloid [10, 12]. The
posterior hyaloid, previously attached, could detach as a result
of these changes, and this could potentially modify the course
of DMO, even leading to its resolution.
Herein, we present findings on a large cohort of patients
receiving intravitreal anti-VEGF therapy with ranibizumab for
DMO and investigate the potential relationship between (1)
VMIA at baseline and (2) the change in the posterior hyaloid
face during the follow-up and functional/anatomical outcomes
following anti-VEGF therapy.
Methods
The medical records of consecutive patients with centre-
involving DMO that met the eligibility criteria for intravitreal
ranibizumab treatment as per the UK National Institute for
Health and Clinical Excellence (NICE) guidelines [13] and
who presented to the Macular Unit, Belfast Health and
Social Care Trust, Belfast, UK, during the period between
December 1, 2013, and March 31, 2014, were reviewed.
Only patients with DMO naive to intravitreal injections of
anti-VEGFs/steroids were included. Patients with a history
of previous laser treatment were also included. Those with a
history of pars plana vitrectomy were excluded.
In keeping with the standard clinical practice at our site,
all patients initiating anti-VEGF therapy received an ocular
examination, which included refraction undertaken by an
optometrist and best-corrected visual acuity (BCVA) mea-
sured with Early Treatment Diabetic Retinopathy Study
(ETDRS) visual acuity charts at baseline, visual acuity
testing obtained using ETDRS visual acuity charts and,
following the refraction obtained at baseline, intraocular
pressure measurement and slit-lamp biomicroscopy. SD-
OCT scans were routinely obtained by trained ophthalmic
photographers at every clinic visit using commercially
available equipment (Spectralis OCT; Heidelberg
Engineering, Heidelberg, Germany). SD-OCTs were ob-
tained in the standard mode (the enhanced depth imaging
mode was not used for the purpose of evaluating DMO).
Grading of the diabetic retinopathy was determined by the
ophthalmologists evaluating the patients in the clinic. Macular
oedema was classified, based on OCT findings, into mild,
moderate and severe as described by the Global Diabetic
Retinopathy Project Group [14]. Grading of the DMO was
determined by one of the investigators (MM) based on OCT
and fundus images.
All intravitreal anti-VEGF injections were performed in a
clean room with topical povidone 5% and topical anaesthetic
before the procedure. The treatment protocol involved three-
monthly ranibizumab injections followed by a pro re nata
regimen thereafter.
Evaluation of the vitreomacular interface
SD-OCT scans were used to obtain data on central retinal
thickness (CRT) values. The CRTwas computed automatical-
ly using built-in retinal mapping software. SD-OCT video
clips (Spectralis OCT; Heidelberg Engineering, Heidelberg,
Germany) from all included patients were evaluated by a se-
nior investigator (NL) masked to clinical findings, including
visual acuity and treatments received; the status of the poste-
rior hyaloid and VMI at baseline and at the last follow-up was
graded (see below) and recorded.
SD-OCT video clips enabled detection of foveal and extra-
foveal traction as well as changes outside the central macular
area and also differentiation between epiretinal membranes
and taut posterior hyaloid. The SD-OCT appearance of the
inner retinal surface was graded based on the International
Vitreomacular Traction Study Group classification of
vitreomacular adhesion, traction, and macular hole as follows:
(a) normal VMA, (b) VMT (Fig. 1a), (c) full-thickness mac-
ular hole (FTMH), (d) lamellar macula hole (LMH), (e)
epiretinal membrane (Fig. 1b) and (f) combined epiretinal
membrane (ERM) and VMT [1].
The status of the posterior hyaloid face (PHF) was also
graded based on the presence or absence of a PHF attach-
ment as (a) totally attached (Fig. 2a), (b) partially attached,
or (c) fully detached (Fig. 2b) at baseline. The occurrence
of a partial or complete detachment of the PHF was also
recorded at the last follow-up visit. The number of images
with insufficient quality for grading as well as those in
which determining the status of the PHF was not possible
was also recorded.
Statistical analysis
The statistical analysis of the data was performed using the
Statistical Package for the Social Sciences, Windows version
21 (SPSS Inc., Armonk, NY). The distribution of continuous
variables was assessed for normality using the Kolmogorov-
Smirnov test, and the transformation was performed, if neces-
sary, to achieve normal distribution. Categorical variables
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were compared using Pearson’s chi-square test. Continuous
variables were compared using the independent samples t test.
General estimating equations (GEE) were used to under-
take the multivariable regression analysis to enable data from
both eyes to be included. GEE models account for the corre-
lation between two eyes from one patient. A multivariable
modelling controlled for age and gender was undertaken. A
second model was also run controlling for those covariates
shown to be significant in the univariate analysis. p values <
0.05 were considered statistically significant.
In patients with both eyes meeting eligibility criteria, data
from both eyes were used. The authors confirm that data col-
lection conformed to the local policy at the Belfast Health and
Social Care Trust; this study was registered with the audit
department (number 4966).
Results
The study cohort included 146 eyes of 100 consecutive pa-
tients with a mean age of 63.5 years at the time of presentation
(range 24–88 years). One hundred thirty-eight eyes (94.5%)
exhibited severe macular oedema, which includes retinal
thickening or hard exudates involving the centre of the fovea.
Eighty-two eyes (56.1%) had no previous macular laser treat-
ment at baseline. The descriptive characteristics of the 100
patients (146 eyes) studied are shown in Table 1; examples
of the features investigated in the study are depicted in Figs. 1
and 2. Patients were followed up for a mean of 9 months
(range 2–14 months). Eyes were treated with ranibizumab
only (i.e. no other anti-VEGFs used) during this period. 9/
146 eyes were lost to follow-up before month 6. The number
of injections per month of follow-up was 0.8 (SD 0.3).
Factors associated with VMIA at baseline
Signs of VMIAwere detected in 28 eyes (18.5%); 19 of these
(70%) had an ERM, 8 (28.5%) had VMT and one (0.5%) had
both VMT and ERM. A statistically significant difference in
mean BCVAwas observed between patients with and without
VMIA, with patients with VMIA having worse vision (45
ETDRS letters in eyes with VMIA compared to 55 ETDRS
letters in eyes without VMIA; p = 0.007). Eyes with VMIA
were more likely to have undergone panretinal photocoagula-
tion but less likely to have had macular laser than eyes without
VMIA (p = 0.006). There was no association between CRT at
presentation and the presence of VMIA. A higher proportion
of patients with VMIA had undergone cataract surgery (p =
0.01). There was no association between the presence of
VMIA and the duration of diabetes, HbA1C level, history of
hypertension or kidney disease.
Presence of VMIA at baseline and treatment
outcomes
Table 2 shows the results of the multivariable regression anal-
ysis undertaken to evaluate associations between the presence
of VMIA at baseline and treatment outcomes adjusted for age,
gender, retinopathy stage at baseline and history of previous
cataract surgery or laser therapy. No statistically significant
associations between the presence of VMIA at baseline and
outcomes following ranibizumab treatment, including the
Fig. 1 SD-OCT scan
demonstrating VMIA, including
VMT (a) and ERM (b) associated
with DMO in two eyes of patients
included in the study
Fig. 2 SD-OCT scans
demonstrating two eyes included
in the study with an attached
posterior hyaloid (a) and with a
detached posterior hyaloid (b)
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Table 1 Descriptive characteristics of the study cohort and univariable analysis comparing eyes with and without VMIA at baseline and eyes with and
without a change in the posterior hyaloid interface during the follow-up
All
(n = 146
eyes)
Presence of
VMIA (n = 28
eyes)
Absence of
VMIA
(n = 118 eyes)
p*~ Change in the posterior hyaloid
interface during follow-up
(n = 22 eyes)
No change in the posterior
hyaloid interface during follow-
up (n = 91 eyes)
p**~
Age (SD) 64 (13) 64 (14) 64 (13) 0.956 60 (15) 64 (13) 0.266
Male sex (%) 61 14 (50) 78 (66) 0.087 17 (74) 55 (60) 0.563
DMduration in years
(SD)
17 (10) 18 (10) 17 (10) 0.540 16 (9) 17 (11) 0.729
HbA1C level in
mmol/L (SD)
66 (16) 63 (17) 66 (16) 0.449 69 (18) 64 (15) 0.284
Baseline BCVA
(SD)
53 (17) 45 (20) 55 (16) 0.007 58 (20) 52 (17) 0.170
Baseline central
retinal thickness
(SD)
536 (140) 522 (128) 539 (143) 0.580 533 (162) 541 (146) 0.814
% history of
hypertension
90 90 91 0.528 87 90 0.726
% history of kidney
disease
6 14 4 0.069 0 4 0.019
Stage of DR
No DR (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mild NPDR (%) 43 (29) 5 (18) 38 (32) 7 (30) 24 (26)
Moderate NPDR
(%)
28 (19) 6 (21) 22 (19) 2 (9) 16 (18)
Severe NPDR (%) 24 (16) 2 (7) 22 (19) 0.035 6 (27) 15 (17) 0.276
Very severe NPDR
(%)
6 (4) 0 (0) 6 (5) 1 (5) 5 (6)
Proliferative DR
(%)
6 (4) 3 (11) 3 (3) 2 (9) 4 (4)
Treated proliferative
DR (%)
39 (27) 12 (43) 27 (23) 4 (18) 27 (30)
Previous ocular surgery
None (%) 116 (80) 17 (61) 99 (84) 0.010 17 (77) 74 (81) 0.783
Cataract surgery
(%)
30 (20) 11 (39) 16 (16) 5 (22) 17 (19)
Previous laser surgery
None (%) 38 (26) 8 (29) 31 (26) 7 (30) 19 (21)
Macular laser (%) 64 (44) 5 (18) 59 (50) 9 (41) 42 (46)
PRP (%) 15 (10) 6 (21) 9 (8) 0.006 1 (5) 11 (12) 0.592
Macular laser + PRP
(%)
28 (19) 9 (32) 19 (16) 5 (23) 18 (20)
Posterior hyaloid status at baseline, n (%)
Totally attached 20 (14) 0 (0) 20 (17) 6 (26) 14 (15)
Partially attached 69 (47) 11 (39) 58 (49) 16 (70) 52 (57)
Totally detached 22 (15) 8 (29) 14 (12) 0.012 0 (0) 22 (24) < 0.001
Could not be
determined
30 (21) 9 (32) 21 (18) 0 (0) 1 (1)
Ungradable 5 (3) 0 (0) 5 (4) 0 (0) 2 (2)
VMIA
Present, n (%) 28 (19) 19 (86) 75 (82) 0.210
Absent, n (%) 118 (81) 3 (14) 16 (18)
Macular status at the final visit
Dry, n (%) 23 (16) 4 (14) 19 (16) 6 (27) 11 (12)
Fluid present, n (%) 118 (81) 24 (86) 94 (80) 0.746 15 (68) 77 (85) 0.182
Ungradable, n (%) 5 (3) 0 (0) 5 (4) 1 (5) 3 (3)
0.8 (0.3) 0.8 (0.3) 0.7 (0.3) 0.145 0.8 (0.3) 0.7 (0.3) 0.290
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change in BCVA or CRT from the baseline to the last follow-
up, and the presence or absence of fluid at the macula at the
last follow-up were identified.
Development/resolution of VMIA
during the follow-up
In this series, no eyes developed VMIA or had resolution of
pre-existing VMIA during the follow-up.
Factors associated with the change in the posterior
hyaloid interface during follow-up
Partial or complete detachment of the posterior hyaloid inter-
face was observed in 22 eyes during the follow-up (15%). A
history of kidney disease (p = 0.019) was the only factor found
to be statistically significantly associated with this occurrence.
Treatment outcomes and changes in the posterior
hyaloid surface during follow-up
Multivariable regression analysis did not reveal any statisti-
cally significant difference between detachment of the poste-
rior hyaloid during follow-up and change in BCVA, number
of injections per month, changes in CRT and status of macula
at follow-up, when corrected for age, gender and history of
kidney disease (Table 3). There was an association of border-
line significance (p = 0.052) between posterior hyaloid de-
tachment and absence of macular fluid at the last follow-up.
Discussion
In the current study, VMIA, as defined by the International
Vitreomacular Traction Study Group, were detected in 18.5%
of patients with DMO, the majority of these being ERM
(70%). VMIAwere more common in patients that had previ-
ously undergone panretinal photocoagulation (PRP) and cata-
ract surgery and less frequent in those that had received mac-
ular laser. Patients with VMIA presented with lower levels of
vision. The presence of VMIA at baseline did not dampen the
functional (VA) or structural (CRT) response to ranibizumab
treatment.
VMIA in patients with DMO
The prevalence of VMIA in patients with DMO identified in
this study appears to be within the previously reported range
(Table 4) [2, 6–10]. It is lower than that reported in a recently
published study, which found an ERM prevalence of 43% in a
group of 77 patients (104 eyes) [10]. This study included eyes
with higher stages of diabetic retinopathy (DR) at presentation
[10].
Previous PRP was associated with the presence of VMIA.
ERM formation may occur as a result of laser panretinal pho-
tocoagulation [15]. It has also been proposed that PRP induces
an angiofibrotic switch by lowering VEGF levels and increas-
ing the ratio of connective tissue growth factor over VEGF,
which may subsequently trigger changes in the vitreomacular
interface [16]. However, as PRP is applied to patients with
Table 1 (continued)
All
(n = 146
eyes)
Presence of
VMIA (n = 28
eyes)
Absence of
VMIA
(n = 118 eyes)
p*~ Change in the posterior hyaloid
interface during follow-up
(n = 22 eyes)
No change in the posterior
hyaloid interface during follow-
up (n = 91 eyes)
p**~
No. of injections per
month of
follow-up (SD)
Change in posterior hyaloid during follow-up, n (%)
None 91 (62) 16 (57) 74 (63)
Complete or partial
detachment
22 (15). 3 (11) 20 (17)
Could not be
determined*
29 (20) 9 (32) 20 (17) 0.210
Ungradable
follow-up images
4 (2) 0 (0) 4 (3)
p < 0.05 is highlighted in italics. BCould not be determined^, not possible for the grader to determine whether the vitreous was fully attached or fully
detached (reflectivity would not be clearly present or absent in the vitreoretinal interface of vitreous cavity). Ungradable, images of inadequate quality for
evaluation
~ Chi-square tests for categorical variables and independent t test for continuous variables
*p, comparison between patients with or without VMIA at baseline
**p, comparison between patients with or without a change in the posterior hyaloid face during the follow-up
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proliferative diabetic retinopathy, a causal relationship between
the pathogenic events related to advanced stages of disease and
the occurrence of VMIA cannot be ruled out. Interestingly, of
those patients with VMIA, only 18% had previously had mac-
ular laser when compared with 50% of those without VMIA. It
is not clear how macular laser could exert this apparent protec-
tive effect on the development of VMIA.
VMIAwere also identified more frequently in patients who
had undergone cataract surgery. Pseudophakia is associated
with an increased incidence of posterior vitreous detachment
[17]. Furthermore, epidemiological studies have established a
link between ERM and previous cataract surgery [18, 19], and
changes in the vitreomacular interface following cataract sur-
gery in otherwise healthy eyes have been documented using
OCT [20]. It is possible that in the context of DR and DMO,
inflammationmay promote a firmer attachment of the vitreous
to the macular area. Under these circumstances, it is possible
that, following cataract surgery, detachment of the vitreous
outside the macula with incomplete separation at the macula
would lead to VMIA.
Lower visual acuity at presentation was found in patients
with VMIA when compared with those without them. This
agrees with findings of other studies [6, 11].
Functional and structural outcomes following
anti-VEGF in the presence of VMIA
Previous studies evaluating the effect of VMIA on the re-
sponse to anti-VEGF agents have reported conflicting results.
Further analysis of a Diabetic Retinopathy Clinical Research
Network study found the absence of Bsurface wrinkling
retinopathy ,^ as determined by colour fundus photography,
to be associated with a significantly better visual outcome
after one year of treatment with ranibizumab [21]. However,
patients were included in this study only if DMO was the
primary cause of vision loss and, therefore, patients with more
severe VMIAwould have been excluded.
A small study by Yoon et al. evaluated the effect of VMIA
(defined as epiretinal membrane and/or anomalous
vitreomacular adhesions) on the response to anti-VEGF treat-
ment in patients with DMO [22]. Only ten eyes with VMIA,
and five without, were included. Eyes with VMIA showed
less improvement in BCVA after 3 anti-VEGF injections.
Wong and colleagues recently reported that the presence of
an ERM at presentation was predictive of a more limited func-
tional (visual acuity) and anatomical (CRT) response in a
study including 77 patients (104 eyes) with DMO [10]. The
prevalence of ERM in this study was high compared with that
observed in the current study (43 versus 13%), and patients
had higher stages of severity of diabetic retinopathy (80%
with pre-proliferative and proliferative disease versus 51%
with severe/very severe non-proliferative diabetic retinopathy
(NPDR) or proliferative DR). In this study, no patients were
classified as having VMT.
A retrospective cohort study of 124 eyes enrolled in the
READ-3 trial found that eyes with evidence of vitreomacular
adhesion at baseline (n = 26) had a greater improvement in
visual acuity than those without VMA (n = 98) at 6 months
following treatment with ranibizumab [12]. In this study, how-
ever, patients with VMTwere excluded from the analysis.
Table 2 Relationship between
the presence of vitreous interface
abnormalities at baseline and
treatment outcomes during
follow-up
Outcome Model 1 Model 2
β CI p β CI p
Change in BCVA 0.019 − 0.024–0.062 0.387 0.013 − 0.022–0.031 0.568
No. of injections per month of
follow-up
1.100 − 0.021–0.048 0.222 1.978 − 1.457–0.878 0.175
Central retinal thickness − 0.002 − 0.001–0.005 0.170 − 0.001 − 0.002–0.004 0.439
Macula status at the final visit 0.105 − 1.320–1.529 0.886 0.650 − 1.277–2.578 0.508
Model 1: corrected for age and sex. Model 2: corrected for age, sex, diabetic retinopathy stage at baseline, history
of cataract surgery and history of previous laser therapy
Table 3 Relationship between
the presence of change in
posterior hyaloid during follow-
up and treatment outcomes
Outcome Model 1 Model 2
β CI p β CI p
Change in BCVA 0.009 − 0.036–0.155 0.694 0.009 − 0.036–0.053 0.707
No. of injections per month of
follow-up
1.318 − 0.772–3.408 0.216 1.241 − 0.820–3.302 0.238
Central retinal thickness 0.000 − 0.003–0.016 0.901 0.001 − 0.003–0.034 0.854
Macula status at the final visit − 1.109 − 2.325–0.107 0.074 − 1.247 − 2.506–0.013 0.052
Model 1: corrected for age and sex. Model 2: corrected for age, sex and history of kidney disease
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A small retrospective case series including 31 eyes studied
the effect of intravitreal injection of bevacizumab on visual
acuity, central macular thickness and total macular volume
after 3 months [23]. VMIA were defined as the presence of
epiretinal membrane or vitreomacular traction on OCT; eight
patients had VMIA. Patients with a history of previous mac-
ular laser were excluded. No statistically significant difference
was found in visual outcome or retinal thickness in patients
with or without VMIA.
A retrospective study of 142 patients (201 eyes) undergo-
ing anti-VEGF therapy found the mean incidence of VMIA to
be 6.43% per year [11]. In this study, patients with VMIA at
baseline were excluded. It was found that patients with poor
baseline visual acuity had a higher chance of developing
VMIA during the follow-up. In accordance with our findings,
there was no statistically significant difference with regard to
visual acuity improvement and reduction in the macular oede-
ma between eyes that developed VMIA and those that did not.
VMIA were classified in the same manner as our study, al-
though images were obtained only with time-domain OCT
[11].
PVD is more prevalent in eyes without DMO [24]. There is
also some evidence suggesting the potential beneficial effect
of pars plana vitrectomy in promoting macular oedema reso-
lution [3–5]. In our study, we found an association of border-
line significance between detachment of the posterior hyaloid
on follow-up and resolution of macular oedema.
This study has several limitations, including its retro-
spective nature, the relatively short follow-up period and
the fact that cataract surgery during the study period was
not systematically recorded. We believe, however, that it
would be unlikely that patients included in this series
would have received cataract surgery during the study pe-
riod. The reasons for this are that it is a standard practice at
our institution for patients with DMO to be treated first
with anti-VEGFs and cataract surgery postponed until
resolution of the DMO has occurred. Also it would be
dffocult that paetients would hacve undergone cataract sur-
gery suring the study period considering waiting times for
cataract surgery and the length of the follow-up of the
patients included in the study. Information about whether
eyes received focal laser treatment or PRP during the peri-
od of the study was, similarly, not systematically recorded.
It would be unlikely that patients would have received
focal laser treatment during the study period as in our
clinics, patients initiating anti-VEGF therapy would have
continued on anti-VEGFs monthly, unless the fluid would
have resolved, during the first year of treatment. A small
proportion of eyes, however, would have received PRP for
active PDR (n = 6; Table 1). Furthermore, although in this
study VMIA did not appear to affect the response to anti-
VEGF therapy, it remains unclear whether resolving the
VMIA surgically in some cases could have yielded to even
better functional results. A randomised clinical trial com-
paring anti-VEGF with anti-VEGF plus vitrectomy for the
treatment of DMO associated with VMIA would be re-
quired to fully address this. The strengths of this study
include the use of an electronic database to identify all
patients examined and treated in our institution during the
period of the study, the relatively high proportion of pa-
tients (eyes) included, the masked evaluation of OCT and
the fact that the data presented was obtained from a clinical
setting and, thus, it is likely that the results observed would
be generalisable.
The findings of our study would suggest that the presence
of VMIA in patients with DMO does not appear to dampen
the response to anti-VEGF therapy.
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Table 4 Prevalence of vitreoretinal interface abnormalities in DMO patients
Study Study design Sample number
(patients/eyes)
Vitreoretinal anomaly
Kim et al. [6] Retrospective, observational 119/164 OCT revealed morphological patterns of DMO patients
with PHT (15.6%)
Ghazi et al. [2] Prospective, observational case series 25/48 ERM or anomalous VMA in 52.1%
Ophir et al. [7] Retrospective study 122/186 VFT in 25 eyes (13.4%) and extra-foveal traction in 20 (10.8%)
Chang et al. [8] Retrospective, observational 76/96 16 eyes (6.6%) had ERM or anomalous VMA
Akbar Khan et al. [9] Retrospective, observational 198/198 Partial vitreomacular separation in 12% and ERM in 14%
Wong et al. [10] Prospective, observational 77/104 43% had foveal-involving ERM and 63% had eccentric ERM
Mikhail et al. (current study) Retrospective, observational 100/146 VMIA in 28 eyes (18.5%): 19 with ERM, 8 with VMT
and 1 with both VMT and ERM
ERM epiretinal membrane, DMO diabetic macular oedema, PHT posterior hyaloid traction, TRD tractional retinal detachment, VMA vitreomacular
adhesion, VFT vitreofoveal traction
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Ethical approval This was part of an audit approved by the Belfast
Health and Social Care Trust (4966); full ethical review was therefore
waived. For this type of study, formal consent is not required.
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